Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Diluted EPS of $4.20 per share (loss) for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.20 | -64.7% |
| 2024 | -$2.55 | +69.8% |
| 2023 | -$8.45 | +74.1% |
| 2022 | -$32.57 | -2424.8% |
| 2021 | -$1.29 | +24.6% |
| 2020 | -$1.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.97 | -31.1% | -10.2% |
| June 30, 2025 | -$0.88 | -72.5% | -7.3% |
| March 31, 2025 | -$0.82 | -51.9% | -10.8% |
| September 30, 2024 | -$0.74 | +80.4% | -45.1% |
| June 30, 2024 | -$0.51 | +96.0% | +5.6% |
| March 31, 2024 | -$0.54 | +93.3% | +85.7% |
| September 30, 2023 | -$3.78 | +57.5% | +70.3% |
| June 30, 2023 | -$12.73 | -4289.7% | -57.2% |
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -64.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Dianthus Therapeutics, Inc. /DE/’s diluted eps has declined by 145.6% (from $1.71 per share (loss) to $4.20 per share (loss)).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: